Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure

New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Source Type: research

Related Links:

Conclusions The 12-month GET-RT program was associated with an improved fitness during 1-yr follow-up, whereas a tendency toward better survival rates was observed during long-term follow-up.
Source: Medicine and Science in Sports and Exercise - Category: Sports Medicine Tags: CLINICAL SCIENCES Source Type: research
Publication date: March 2019Source: Human Pathology: Case Reports, Volume 15Author(s): Yuichi Shibui, Kenichi Kohashi, Ichiro Sakamoto, Kenichiro Yamamura, Yoshinao OdaAbstractA long duration of Fontan circulation can cause fibrosis, cirrhosis of the liver and liver cancer. There have been some reports of hepatocellular carcinoma occurring after the Fontan procedure (FP), and we encountered a case of intrahepatic cholangiocarcinoma (ICC) after the FP. We herein report the case of 33-year-old man who developed ICC after receiving the FP. At five years of age, the patient underwent the original FP. At 16 years of age, he r...
Source: Human Pathology: Case Reports - Category: Pathology Source Type: research
Publication date: 16 October 2018Source: Cell Reports, Volume 25, Issue 3Author(s): Arpita Chowdhury, Abhishek Aich, Gaurav Jain, Katharina Wozny, Christian Lüchtenborg, Magnus Hartmann, Olaf Bernhard, Martina Balleiniger, Ezzaldin Ahmed Alfar, Anke Zieseniss, Karl Toischer, Kaomei Guan, Silvio O. Rizzoli, Britta Brügger, Andrè Fischer, Dörthe M. Katschinski, Peter Rehling, Jan DudekSummaryMitochondria fulfill vital metabolic functions and act as crucial cellular signaling hubs, integrating their metabolic status into the cellular context. Here, we show that defective cardiolipin remodeling, upon loss...
Source: Cell Reports - Category: Cytology Source Type: research
Journal Name: Clinical Chemistry and Laboratory Medicine (CCLM) Issue: Ahead of print
Source: Clinical Chemistry and Laboratory Medicine - Category: Laboratory Medicine Source Type: research
CONCLUSION: Once considered extremely rare, AMIC seems to be underrecognized, probably because of the false attribution of heart failure or hypertrophy to other causes. Certain biomarkers (cTnI, BNP) and imaging findings may lead to early diagnosis and enhance survival. PMID: 30323009 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
Condition:   Chronic Heart Failure Intervention:   Drug: Ivabradine Sponsor:   Getz Pharma Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Heart Failure;   Congestive Heart Failure Intervention:   Drug: Bumetanide 1 MG Sponsor:   Centro en Insuficiencia Cardiaca, Mexico Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Heart Failure Intervention:   Drug: Ivabradine Sponsor:   Getz Pharma Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
No one ever had fun visiting the cardiologist. ­Regardless of how good the doc might be, it’s always a little scary thinking about the health of something as fundamental as the heart. But there are ways to take greater control—to ensure that your own heart health is the best it can be—even if you have a family history of cardiovascular disease. Although 50% of cardiovascular-disease risk is genetic, the other 50% can be modified by how you live your life, according to Dr. Eugenia Gianos, director of Women’s Heart Health at Lenox Hill Hospital in New York City. “This means you can greatly ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Baby Boomer Health heart health Source Type: news
Abbott shares slipped in pre-market trading today after the company narrowed its earnings outlook for the rest of the year, after just meeting both its own forecast and the consensus Wall Street outlook. The Chicago-area healthcare giant’s profits for the three months ended Sept. 30 were off -6.6% at $563 million, or 32¢ per share, despite sales growth of 12.1% to $7.66 billion compared with Q3 2017. Adjusted to exclude one-time items, earnings per share were 75¢, dead even with the top end of Abbott’s guidance and the average on The Street, where analysts were looking for sales of $7.65 billion. &ldq...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured MassDevice Earnings Roundup Wall Street Beat Abbott Source Type: news
More News: Cardiology | Heart | Heart Failure | Internal Medicine